Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03033589 · ClinicalTrials.gov registry record · NA
Femoral Nerve Block Versus Adductor Canal Nerve Block for Peri-Operative Analgesia Following Anterior Cruciate Ligament (ACL) Reconstruction: Evaluation of Post-operative Pain and Strength
A NA study, sponsored by Henry Ford Health System.
- Completed
- Registry status
- NA
- Development phase
- 78
- Enrollment target
NCT03033589 is a NA study that has completed, run by Henry Ford Health System. The registered enrollment target is 78 participants.
The verdict
NCT03033589, a NA study, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- NA
- Development phase
- 78 participants
- Enrollment target
Study Summary
All patients over the age of 16 undergoing primary or revision anterior cruciate ligament reconstruction with the use of bone-patellar-bone autograft are eligible for the study. Patients will be randomized pre-operatively to receive either an adductor canal nerve block (single injection) or a femoral nerve block (single injection). Post-operatively, the primary outcome measures of pain level using visual analog scale as well as narcotic and non-narcotic analgesic requirements will be measured.
Interventions
- DRUG Marcaine 0.25 % Injectable Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2016-05 |
| Est. Completion | 2017-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03033589
The ClinicalTrials.gov registry entry for NCT03033589 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Marcaine 0.25 % Injectable Solution is the first listed.
NCT03033589 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03033589 about?
NCT03033589 is a clinical study titled "Femoral Nerve Block Versus Adductor Canal Nerve Block for Peri-Operative Analgesia Following Anterior Cruciate Ligament (ACL) Reconstruction: Evaluation of Post-operative Pain and Strength". All patients over the age of 16 undergoing primary or revision anterior cruciate ligament reconstruction with the use of bone-patellar-bone autograft are eligible for the study. Patients will be randomized pre-operatively to receive either an adductor canal nerve block (single injection) or a femora...
What is the current status of trial NCT03033589?
This trial is currently completed. It is a NA study. The enrollment target is 78 participants. The study started on 2016-05. Estimated completion is 2017-12-31.
What interventions are being tested in trial NCT03033589?
The interventions under investigation include: Marcaine 0.25 % Injectable Solution (DRUG).
Who is sponsoring clinical trial NCT03033589?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.